Diabetes Test Measures C-Peptide Levels

A new blood test measures levels of C-peptide in blood, which are about five to six times greater than insulin levels and more stable.

Measurement of C-peptide levels allows doctors to differentiate between type 1 and type 2 diabetes. This measurement can also indicate the need for progression to insulin therapy in type 2 diabetes. In addition, it can be used to determine the cause of hypoglycemia, and to monitor recovery after the removal of an insulin-producing tumor of the pancreas. Furthermore, a recent study has linked elevated levels of C-peptide with an increased risk of colorectal cancer in men with diabetes.

"Our new C-peptide test is a substantial product addition to our current diabetic line of tests that help detect the onset of diabetes,” remarked Zachary Irani, CEO of Biomerica, Inc. (Newport Beach, CA, USA), which developed the test. "The introduction of this product to our already existing customer base should not only result in increased sales, but should enhance Biomerica's presence in the clinical laboratory diabetes market.”

Biomerica is a global medical technology company, whose diagnostics division manufactures and markets advanced diagnostic products for the early detection of medical conditions and serious diseases.




Related Links:
Biomerica